| 词条 | Fulranumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 458274903 | type = mab | image = | alt = | mab_type = mab | source = u | target = NGF | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 902141-80-4 | ATC_prefix = none | ATC_suffix = | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 0E986JU40I | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | C=6446 | H=9930 | N=1718 | O=2018 | S=50 | molecular_weight = 145.39 kg/mol | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | KEGG_Ref = {{keggcite|changed|kegg}} | KEGG = D09907 }}Fulranumab is a monoclonal antibody against nerve growth factor.[1] It was designed for the treatment of pain.[2]Johnson & Johnson licensed the drug from Amgen in a deal valued at around US$425 million in 2008. In 2016 Johnson & Johnson discontinued all phase III trials of fulranumab and returned the rights to its originator. The company said the decision was based on "strategic portfolio prioritisation and was not based on any emerging safety concerns from the phase III clinical studies with fulranumab" in osteoarthritic pain.[3] See also
References1. ^Monoclonal Antibodies Targeted Against Nerve Growth Factor For the Treatment of Chronic Pain, By Ken Verburg, PhD - Medicines Development Group, Pfizer Inc., Arthritis Advisory Committee Meeting, 12 March 2012 {{Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems}}{{Growth factor receptor modulators}}{{monoclonal-antibody-stub}}{{analgesic-stub}}2. ^{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/fulranumab.pdf}} 3. ^J&J drops NGF blocker fulranumab, Article by Phil Taylor, 4th April 2016, PMLiVE 1 : Johnson & Johnson |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。